Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/205938
DC FieldValue
dc.titleCorrection of Murine Diabetic Hyperglycaemia With A Single Systemic Administration of An AAV2/8 Vector Containing A Novel Codon Optimized Human Insulin Gene
dc.contributor.authorUin, Gan Shu
dc.contributor.authorMaria, Notaridou
dc.contributor.authorYing, Fu Zhen
dc.contributor.authorOnn, Lee Kok
dc.contributor.authorChuan, Sia Kian
dc.contributor.authorChunilal, Nathwani Amit
dc.contributor.authorMarco, Della Peruta
dc.contributor.authorYorke, Calne Roy
dc.date.accessioned2021-11-11T07:42:40Z
dc.date.available2021-11-11T07:42:40Z
dc.date.issued2016-01-01
dc.identifier.citationUin, Gan Shu, Maria, Notaridou, Ying, Fu Zhen, Onn, Lee Kok, Chuan, Sia Kian, Chunilal, Nathwani Amit, Marco, Della Peruta, Yorke, Calne Roy (2016-01-01). Correction of Murine Diabetic Hyperglycaemia With A Single Systemic Administration of An AAV2/8 Vector Containing A Novel Codon Optimized Human Insulin Gene. CURRENT GENE THERAPY 16 (1) : 65-72. ScholarBank@NUS Repository.
dc.identifier.issn15665232
dc.identifier.issn18755631
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/205938
dc.description.abstractWe report the correction of hyperglycemia of STZ induced diabetic mice using one intravenous systemic administration of a single stranded serotype 8 pseudotyped adeno-associated virus (ssAAV2/8) vector encoding the human proinsulin gene under a constitutive liver specific promoter. In vivo dose titration experiments were carried out and we identified an optimal range that achieved maintenance of euglycaemia or a mild diabetic condition for at least 9 months and ongoing to beyond 1 year for some animals, accompanied by human C-peptide secretion and weight gain. Further DNA codon optimization of the insulin gene construct resulted in approximately 3-10 times more human C-peptide secreted in the blood of codon optimized treated animals thereby reducing the number of vector particles required to achieve the same extent of reduction in blood glucose levels as the non-codon optimized vector. The constitutive secretion of insulin achieved with a single administration of the vector could be of therapeutic value for some diabetic patients.
dc.language.isoen
dc.publisherBENTHAM SCIENCE PUBL LTD
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectGenetics & Heredity
dc.subjectGene therapy
dc.subjectDiabetes
dc.subjectInsulin
dc.subjectAAV
dc.subjectCodon optimization
dc.subjectLONG-TERM SAFETY
dc.subjectGLYCEMIC CONTROL
dc.subjectHEMOPHILIA-B
dc.subjectTHERAPY
dc.subjectEXPRESSION
dc.subjectRATS
dc.subjectMICE
dc.subjectHEPATOCYTES
dc.subjectFIBROBLASTS
dc.subjectREVERSAL
dc.typeArticle
dc.date.updated2021-11-10T06:39:36Z
dc.contributor.departmentMEDICINE
dc.description.sourcetitleCURRENT GENE THERAPY
dc.description.volume16
dc.description.issue1
dc.description.page65-72
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2016CGTAAVPaper.pdfAccepted version604.46 kBAdobe PDF

CLOSED

Published

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.